Zoonotic & Vector-Borne Diseases

Trial demonstrates promising results for oral treatment towards the disease's vector.

Innovative treatments, challenging prevention, and impact of climate change.

The impact of the new surveillance criteria on case identification.

A senior microbiologist gives audiences of sister brands, Infection Control Today and Contagion, an insight into leishmaniasis, a potentially fatal disease.

Oregon resident catches plague through a cat-to-human transmission.

First victim of the Alaskapox Virus highlights the need for increased research.

Study offers new insight into the relationship between Zika Virus and Dengue Virus in tropical regions.

Phase 3 trial is highly effective in preventing symptomatic disease.

CDC's preventive strategies against the world's most prevalent mosquito-borne disease.

Study examines the complexity between human health and tick-borne diseases.

A new human trial aims to prevent the fatal, zoonotic-borne disease.

Valneva’s VLA1553 (Ixchiq) vaccine was shown to met its preliminary endpoint, with 98.9% of participants reaching protective levels of chikungunya virus neutralizing antibodies 1 month after vaccination.

When implemented broadly, malaria vaccines can have a significant impact on public health.

The Biden Administration addresses antimicrobial resistance with new project, company voluntarily recalls its antifungal, and a fatal case of the plague is reported in the US.

As we mark this awareness day, education and immunization has helped the United States make great strides in preventing the viral disease, but globally more work needs to be done.

Earlier this year, the company announced its first foray into these types of infections in developing vaccines for the tickborne infection utilizing its mRNA vaccine platform.

The zoonotic virus has claimed 2 lives as Indian officials work to identify potential contacts and get the virus under control.

If approved, the investigational vaccine would be available to people 18 years and older.

The agency says additional time is needed to decide upon a phase 4 program.

With recent reports of this vector-borne illness in the continental United States, there is concern this might become endemic in the country again.

The vaccine is steps behind another Chikungunya vaccine candidate from Valneva, which is currently under priority review by the FDA.

Very few Lyme disease studies consider sex- and gender-based differences. Is this flawing the research?

Find out why the FDA requested additional data and what this means for dengue prevention.

6 malaria cases were confirmed in Florida and 1 in Texas, with no connection to international travel.

The federal agency has identified a total of 5 cases in Florida and Texas within the last two months.